ASA: Embolization of MMA Cuts Risk for Subsequent Subdural Hematoma, Surgery
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Feb. 14, 2024 -- For patients with symptomatic subacute or chronic subdural hematoma (SDH), embolization of the middle meningeal artery (MMA) as an adjunct to surgery reduces the risk for subsequent SDH and need for surgical drainage, according to a study presented at the annual American Stroke Association International Stroke Conference, held from Feb. 7 to 9 in Phoenix.
Jared Knopman, M.D., from Weill Cornell Medical College in New York City, and colleagues examined the safety and effectiveness of Onyx Liquid Embolic System embolization of the MMA as an adjunct to conventional treatment for patients with symptomatic subacute or chronic SDH in a trial that enrolled 400 individuals across 39 U.S. centers. Individuals who met the criteria for surgical evacuation were randomly assigned to receive surgery alone or surgery with adjunctive MMA embolization in a 1:1 ratio.
The researchers found that subsequent subdural hematoma within 90 days and need for surgical drainage occurred in 4.1 and 11.3 percent of those who underwent surgery plus embolization and surgery alone, respectively. Increasing disability and neurological dysfunction were comparable in both groups at 90 days after surgery, occurring in 11.9 and 9.8 percent of patients, respectively. Overall, 2 percent of patients who received embolization had serious adverse events attributed to embolization.
"The EMBOLISE trial showed that there was a nearly threefold reduction in re-operation for patients that were treated with surgery plus embolization," coauthor Jason Davies, M.D., Ph.D., from the State University of New York at Buffalo, said in a statement. "Fewer trips to the operating room mean less potential for pain, complications, recovery, and expense for the patient."
The study was funded by Medtronic Neurovascular Clinical Affairs. The Onyx Liquid Embolic System is manufactured by EV3, which is owned by Medtronic.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted February 2024
Read this next
Perioperative Chemo Improves Progression-Free Survival in Pancreatic Cancer
TUESDAY, July 2, 2024 -- For patients with resectable pancreatic ductal adenocarcinoma (PDAC), the 12-month progression-free survival (PFS) may be increased with neoadjuvant...
Few Patients With Positive Margins After Basal Cell Excision Have Recurrence
MONDAY, July 1, 2024 -- Among patients with incompletely excised basal cell carcinoma (BCC), only about 16 percent with positive histopathologic margins have clinical recurrence...
Lower Cognitive Function in Adolescence Linked to Stroke Risk
FRIDAY, June 28, 2024 -- Lower cognitive function in adolescence is associated with increased risk of early-onset stroke, according to a study published online June 27 in the...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.